BPC-157 Complete Drug-Drug Interaction Profile

The short answer: BPC-157 interactions are unknown

There is not a clinically validated “complete interaction profile” for BPC-157. The phrase is useful as a search topic, but it should not imply that interaction probabilities, contraindicated combinations, monitoring intervals, or dose adjustments have been measured in people.

FDA's 2026 scientific review found insufficient clinical safety information to characterize BPC-157 and found no human studies using the proposed oral, subcutaneous, nasal, or transdermal routes. The agency found limited reports involving other routes and emphasized that the available information could not establish a clinical safety profile 1. A 2025 systematic review of orthopedic use similarly found no clinical safety data, despite identifying a small retrospective report of intra-articular use 2.

That evidence gap matters for interactions. Interaction studies normally evaluate whether one substance changes another drug's exposure, metabolism, clearance, or clinical effect. Those studies have not been published for BPC-157.

What animal research can—and cannot—tell us

Animal studies describe BPC-157 activity in models involving blood vessels, gastrointestinal injury, inflammation, and neurotransmitter systems. A 2018 review, for example, discusses vascular and gastrointestinal experiments, including work involving anticoagulants 3. Older rat experiments also examined adrenergic and dopaminergic systems 4.

These studies may help researchers decide what to test next. They do not establish that BPC-157:

• increases or decreases a person's INR;
• potentiates aspirin, warfarin, apixaban, or clopidogrel;
• causes serotonin syndrome with antidepressants;
• changes opioid tolerance in people;
• lowers human blood pressure when combined with antihypertensives;
• changes the absorption or exposure of GLP-1 medicines or thyroid hormone; or
• induces or inhibits CYP drug-metabolizing enzymes.

The previous version of this page converted mechanistic observations into clinical tiers and fixed monitoring schedules. That went beyond the evidence. The defensible conclusion is uncertainty, not a list of proven interactions.

BPC-157 with anticoagulants or antiplatelet drugs

There are no human studies measuring BPC-157 with warfarin, direct oral anticoagulants, aspirin, or P2Y12 inhibitors. Animal coagulation findings cannot predict whether a particular combination raises bleeding risk, lowers it, or has no clinically meaningful effect.

This is especially important because anticoagulants and antiplatelet drugs have high-consequence indications. Do not start BPC-157, stop a prescribed blood thinner, or change its dose on the basis of an online interaction chart. The prescriber managing the anticoagulant should evaluate the combination.

BPC-157 with NSAIDs

Rodent studies have tested BPC-157 in models of NSAID-related gastrointestinal injury. Those experiments are sometimes described online as proof that BPC-157 “protects the stomach” when ibuprofen, naproxen, or another NSAID is used. They do not show that BPC-157 prevents ulcers or bleeding in people, and they do not establish a safe human combination.

For someone using an NSAID, the established risk assessment still depends on the NSAID, dose, duration, ulcer history, kidney function, age, and concurrent medicines. BPC-157 should not be treated as gastroprotection.

BPC-157 with opioids or other CNS-active medicines

Animal studies involving dopamine signaling or opioid-related behaviors are not human interaction trials. There is no validated evidence that BPC-157 changes analgesia, withdrawal, respiratory depression, sedation, antipsychotic response, or antidepressant response in people.

That means fixed recommendations such as adding electrocardiograms, changing an opioid dose, or avoiding driving for a prescribed number of days cannot be derived from the BPC-157 literature. New neurologic, mood, sedation, or pain-control changes warrant clinical review regardless of the suspected cause.

BPC-157 with blood-pressure medicines

Claims about additive hypotension are based on proposed nitric-oxide effects, not measured human combinations. No published interaction study defines the effect of BPC-157 with ACE inhibitors, ARBs, calcium-channel blockers, beta-blockers, nitrates, or PDE5 inhibitors.

People who develop fainting, severe dizziness, chest pain, or shortness of breath should seek appropriate medical assessment. A theoretical mechanism is not enough to identify which substance caused a symptom.

BPC-157 with hormones, GLP-1 drugs, or thyroid medicine

There are no established BPC-157 interaction data for testosterone, estrogen, progesterone, semaglutide, tirzepatide, insulin, sulfonylureas, or levothyroxine. Online claims about altered gastric emptying, thyroid absorption, glucose response, or hematocrit are extrapolations unless a specific human study demonstrates the combination.

Patients should not separate injections by an invented interval or schedule extra laboratory tests solely because a theoretical pathway overlaps. A clinician may still recommend monitoring based on the approved medicine, the underlying condition, or the person's symptoms.

BPC-157 with transplant or cancer treatment

The absence of interaction data is particularly consequential when a medicine is being used to prevent organ rejection or treat cancer. Preclinical angiogenesis or cytokine findings cannot determine how BPC-157 affects anti-VEGF therapy, chemotherapy, tacrolimus, cyclosporine, or mycophenolate in a patient.

These medicines have narrow therapeutic goals and serious consequences if treatment is disrupted. Any contemplated BPC-157 use should be discussed with the specialist managing that therapy before exposure.

Is there a standard BPC-157 dose or interaction-monitoring protocol?

No FDA-approved BPC-157 label defines a dose, route, cycle length, taper, contraindication list, laboratory panel, or interaction-monitoring schedule. The 200–500 microgram regimens and four-to-eight-week “cycles” commonly repeated online are not an FDA-approved dosing standard.

FDA's July 2026 Pharmacy Compounding Advisory Committee materials evaluated BPC-157 free base and acetate and proposed that they not be added to the 503A Bulks List 5. That regulatory review is separate from the scientific question of a specific drug interaction, but it confirms why approved-label interaction instructions do not exist.

A practical medication-review framework

When evidence is this limited, the useful approach is to identify uncertainty accurately:

1. List every exposure. Include prescriptions, nonprescription medicines, supplements, alcohol, cannabis products, and the exact BPC-157 formulation and route.
2. Identify high-consequence therapies. Anticoagulants, antiplatelet drugs, transplant medicines, cancer therapy, insulin, anti-seizure medicines, and drugs with therapeutic monitoring deserve specialist review.
3. Do not invent spacing or dose adjustments. There is no evidence-based number of hours that eliminates a BPC-157 interaction.
4. Document timing. If a new symptom occurs, record when each product was started, stopped, or changed.
5. Report suspected adverse events. FDA MedWatch accepts reports involving compounded products and suspected interactions at fda.gov/medwatch.